Does Progesterone Cause Brain Tumors? What the Research Actually Shows
If you've spent any time researching hormone therapy, you've probably run across a headline linking a hormone medication to brain tumors, specifically meningiomas, and the headline probably said "progesterone." That's not accurate. Progesterone, the hormone your body makes and the one used in bioidentical hormone therapy, has no meningioma signal in the research. What's actually linked to meningioma risk is one specific synthetic progestin, a molecule that isn't progesterone at all, that gets lumped into the same casual "progesterone" language most headlines use for anything that touches that receptor.
Why Meningiomas Are Even Part of This Conversation
Progestogen is the umbrella term for any compound that activates the progesterone receptor. Progesterone is the specific hormone your body makes, and the one used in bioidentical hormone therapy. Progestin is the term for the synthetic compounds under that same umbrella, DMPA, cyproterone acetate, and others, that are built to activate the same receptor without being the same molecule. Headlines routinely collapse all three into "progesterone," which is exactly how a finding about one synthetic progestin turns into fear about the natural hormone.
Meningiomas are tumors of the meninges, the membrane surrounding the brain and spinal cord. They're more common in women than men, and most of them express progesterone receptors, which is the biological reason hormone exposure is relevant to their growth at all. That fact alone gets flattened into "progesterone causes brain tumors" in a lot of casual reporting, which is where the confusion starts. Receptor expression means these tumors can respond to progestogen signaling. It doesn't mean every compound that binds that receptor behaves the same way once it does.
What the Actual Data Shows
The clearest picture comes from a French national case-control study covering the entire population health database, comparing women who had surgery for meningioma against matched controls, and looking at exposure to several specific progestogens. For depot medroxyprogesterone acetate, DMPA, the injectable contraceptive sold as Depo-Provera, women with a year or more of use had 5.55 times the odds of a meningioma requiring surgery compared to non-users (95% CI 2.27 to 13.56) (Roland N et al., BMJ, 2024 — PMID: 38537944). That's a real, statistically significant signal.
In that same study, using the same population and the same methodology, progesterone, dydrogesterone, and the levonorgestrel IUD showed no excess risk. Not a smaller risk. No excess risk. This is the detail that gets lost when the finding becomes a headline: the study that found DMPA's risk is the same study that found bioidentical progesterone didn't carry it.
A separate, earlier French cohort study found something similar with high-dose cyproterone acetate, a progestin used for hormone-driven acne and hirsutism and, in some countries, as part of feminizing hormone therapy: a strong dose-response relationship, meaning more cumulative exposure meant more risk, and a meaningful drop in risk after the medication was stopped (Weill A et al., BMJ, 2021 — PMID: 33536184). That dose-response and reversibility pattern is itself informative. It behaves like a drug effect tied to a specific compound, not a universal property of progesterone signaling.
Why the Same Receptor Doesn't Mean the Same Risk
DMPA and cyproterone acetate are synthetic molecules, engineered to activate the progesterone receptor without being the molecule your body actually makes. That's not a claim that every synthetic progestin carries the same risk, or even that all of them carry a risk here at all. Dydrogesterone, another synthetic compound, showed no excess risk in the same Roland study, right alongside actual progesterone. Cyproterone acetate's meningioma risk is far larger than DMPA's, over twelvefold odds compared to roughly threefold in pooled data across studies (Hudelist B et al., EClinicalMedicine, 2026 — PMID: 41732194), a different compound with its own distinct risk profile, not a shared "synthetic penalty" applied evenly across the class. What's consistent is this: every documented risk signal in this research, whatever its size, has come from a synthetic compound. None has ever come from actual progesterone, in this study or any other that's looked for it. Your receptors were built to receive the hormone your body makes. Synthetic analogs, each with their own chemistry and their own specific interactions, carry more potential for this kind of off-target effect than the molecule you were designed around, even when the size and nature of that risk varies compound to compound. Micronized progesterone isn't an analog carrying its own version of that risk. It's the real thing, and the body responds to it accordingly.
This is the same underlying principle behind why conjugated equine estrogen and estradiol behave so differently on clotting risk. A hormone structure your body wasn't built to receive interacts with your receptors differently than the hormone it was built around, and the adverse effects cluster around the synthetic, non-human versions, not the bioidentical ones. This meningioma finding isn't an isolated oddity. It's one more example of a pattern that shows up every time you actually separate synthetic hormones from bioidentical ones instead of lumping them into one category.
A Familiar Pattern
A patient came in having read about the meningioma association and was ready to stop hormone therapy altogether, including the micronized progesterone she'd been taking as part of a well-tolerated regimen. She'd never been on DMPA or cyproterone acetate. Walking through what the actual studies looked at, and which specific compounds carried the signal, versus what she was actually taking, resolved the concern without requiring her to stop something that was working for her. The fear wasn't irrational, the headlines she'd seen genuinely didn't make the distinction. The underlying data did.
What This Actually Means for You
If you've used DMPA long-term or high-dose cyproterone acetate, this is worth a real conversation with your prescriber, not because the absolute risk is high (it isn't, meningioma remains a rare outcome even with the relative risk increase), but because it's a legitimate, dose- and duration-dependent signal worth factoring into a long-term contraceptive or treatment plan. If you're using micronized, bioidentical progesterone as part of a hormone optimization regimen, the studies that specifically looked for this risk didn't find it. That's a meaningfully different starting point than "progesterone is under a cloud of suspicion," which is the impression a lot of secondhand reporting leaves people with.
The Broader Point
A finding about one specific synthetic compound keeps getting reported as if it were about an entire hormone category, and the detail that actually matters, which molecule, what dose, what route, gets lost in the process. It happened with estrogen and clotting risk, where conjugated equine estrogen and estradiol carry different risk profiles that regularly get blurred into one undifferentiated "estrogen" conversation. It's happening here too, with the same underlying cause: a synthetic molecule your body wasn't built to receive causes a problem, and a bioidentical hormone absorbs the blame by association.
Check which specific compound a headline like this is actually about before it changes how you think about a therapy that's working for you.
Has a headline like this ever made you want to stop something that was actually helping you?
A free consultation is a good place to start that conversation, no commitment required, just a chance to look at the full picture together.
— Dr. Darrell Wilcox | @wellnessdoc_4everyoung on Instagram
References
Roland N, Neumann A, Hoisnard L, Duranteau L, Froelich S, Zureik M, Weill A. Use of progestogens and the risk of intracranial meningioma: national case-control study. BMJ. 2024;384:e078078 — PMID: 38537944.
Weill A, Nguyen P, Labidi M, Cadier B, Passeri T, Duranteau L, Bernat AL, Yoldjian I, Fontanel S, Froelich S, Coste J. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ. 2021;372:n37 — PMID: 33536184.
Hudelist B, Roux A, Huet-Mignaton E, Dufaure-Gare I, Moiraghi A, Elia A, Seneca M, Provost C, Benzakoun J, Gehanno A, Oppenheim C, Zanello M, Pallud J. Progestogen use and the risk of intracranial meningioma: a systematic review and meta-analysis. EClinicalMedicine. 2026;92:103791 — PMID: 41732194.
This content is for educational purposes only and does not constitute medical advice. Decisions about contraception and hormone therapy should be made individually with a physician, taking into account personal and family medical history. Individual results vary, and no outcome is guaranteed. Dr. Wilcox is licensed to practice in Texas, Arizona, Colorado, Oregon, and Florida.
